Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.
0/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.6%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
APA
Di Federico A, Angelicola S, et al. (2026). Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.. JCO precision oncology, 10, e2600034. https://doi.org/10.1200/PO-26-00034
MLA
Di Federico A, et al.. "Erratum: Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations.." JCO precision oncology, vol. 10, 2026, pp. e2600034.
PMID
41610376 ↗
같은 제1저자의 인용 많은 논문 (4)
- Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced -Mutated NSCLC: A Systematic Review and Meta-Analysis With Reconstructed Individual Patient Data.
- TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRAS Inhibitors.
- Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis.
- First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.